Crohn’s disease is a type of inflammatory bowel disease, where the gastrointestinal tract becomes inflamed, which results in symptoms such as diarrhoea, stomach aches and fatigue. We were delighted to speak with Reinier van Linschoten (Franciscus Gasthuis & Vlietland; and Erasmus MC, Rotterdam, the Netherlands) around the health burden of Crohn’s disease, the disadvantages of current adalimumab dosing regimens in the maintenance of remission and the hot topics and latest research in Crohn’s disease.
The abstract entitled ‘CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL’ (Abstract no: OP106) was presented at UEG Week, October 8 – 11, 2022.
Questions
- Could you give us a brief overview of the health burden of Crohn’s disease? (0:22)
- What are the disadvantages of current dosing regimens in the maintenance of remission in patients with Crohn’s disease? (1:28)
- What are the hot topics and latest research you are looking forward to exploring in Crohn’s disease? (2:30)
Disclosures: Reinier van Linschoten has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
